Article
Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients.
Antiviral therapy - 1 Jan 2011
Baleriola Cristina, Rawlinson William D, Dore Gregory J, Chaverot Sandra, Stelzer-Braid Sacha, Yoshihara Motoko, Crawford Darrell, Sievert William, McCaughan Geoffrey, Weltman Martin, Cheng Wendy, Rizkalla Bishoy, Dubois Dwight, Thommes James, Roberts Stuart
Abstract excerpt
BACKGROUND: We examined the detection of low-level viraemia at week 24 as a predictor of sustained virological response (SVR) and viral relapse/breakthrough, and the agreement between the Roche Cobas TaqMan™ HCV RNA assay (TaqMan) and Roche Cobas(®) Amplicor HCV qualitative assay (Amplicor; both Roche Molecular Diagnostics, Pleasanton, CA, USA) for detection of low-level viraemia. METHODS: A total of 871...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.